<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Patents on FinanClub</title>
    <link>https://finan.club/tags/patents/</link>
    <description>Recent content in Patents on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 01 Mar 2024 09:07:14 +0000</lastBuildDate><atom:link href="https://finan.club/tags/patents/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>TGTX</title>
      <link>https://finan.club/us/tgtx/</link>
      <pubDate>Fri, 01 Mar 2024 09:07:14 +0000</pubDate>
      
      <guid>https://finan.club/us/tgtx/</guid>
      <description>score:-39
Chances: TG Therapeutics beat earnings expectations in Q4 2023, indicating strong financial performance Sales of its multiple sclerosis treatment met expectations, leading to a surge in TGTX stock The issuance of additional patents by the USPTO extends the exclusivity of ublituximab through 2042, securing the company’s position in the market Risks: TG Therapeutics is not one of the most popular stocks among hedge funds, which may indicate lower investor confidence The company’s future revenue guidance for BRIUMVI is set between $220 - $260 million, and any deviation from this range could impact the stock price The launch of BRIUMVI in Europe by its ex-US partner introduces potential regulatory and market challenges Score:-39 chances characters count - risks characters count = -39</description>
    </item>
    
  </channel>
</rss>
